-
6m 28s
-
8m 35sPart 3 | Session 4 The STEMI-DTU Trial – Primary Unloading and Delayed Reperfusion in STEMI
-
4m 47s
-
13m 52sPart 3 | Session 6 ACC 2026 with Dr Mehran: Leadership, Vision, and the Future of the College
-
5m 17sPart 3 | Session 7 Heart Failure in 2026: Practical Therapy Lessons From ACC.26
-
6m 14sPart 3 | Session 8 RECOVER-Autonomic - Ivabradine for Post-COVID POTS
-
9m 23sPart 3 | Session 9 ORBITA-CTO - PCI Versus Placebo for Chronic Total Occlusion in Stable Angina
-
7m 21sPart 3 | Session 10 CHIP-BCIS3 – Percutaneous LV Unloading in High-Risk PCI
-
16m 1sPart 3 | Session 11 Dr Reddy & Dr Nair on CHAMPION-AF: Redefining Stroke Prevention
-
7m 26sPart 3 | Session 12 FAST III - FFR vs vFFR to Guide Revascularisation
-
5m 34sPart 3 | Session 13 AI-Based Retinal Imaging for Atherosclerotic Cardiovascular Risk
-
4m 5sPart 3 | Session 14 CORALreef — Durability of Enlicitide for Lipid Lowering in Hypercholesterolaemia
-
5m 18sPart 4 | Session 1 STEMI-DTU, GOFRESH, and HI-PEITHO
-
3m 7sPart 4 | Session 2 SURPASS CVOT, HI-PEITHO, SURVIV
-
5m 8sPart 4 | Session 3 Top Takeaways from the 2026 Dyslipidaemia Guidelines
-
2m 21sPart 4 | Session 4 3 ACC.26 Highlights for the Cardiology Pharmacist
-
10m 19s
-
25m 1sPart 1 | Session 1 CHAMPION-AF: LAA Closure vs OAC in AF Outcomes
-
18m 33sPart 1 | Session 2 ALERT: Under-treatment in AS and MR
-
26m 37sPart 1 | Session 3 PRO-TAVI: TAVI With or Without Routine PCI
-
19m 43sPart 1 | Session 4 Dig-RHD: Digoxin in Rheumatic Heart Disease
-
6m 44sPart 2 | Session 1 VESALIUS-CV, KARDINAL, CHIP-BCIS3 & More
-
9m 4sPart 2 | Session 2 CHAMPION-AF, HI-PEITHO, STEMI-DTU
-
5m 51sPart 3 | Session 1 Door to Unload Randomized Clinical Trial
ACC.26 – Dr Ajay Kirtane (NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, US) discusses the ALL-RISE trial (NCT05893498), a large-scale, global, prospective, randomised, multicentre study comparing FFRangio-based, angiography-derived coronary physiology with conventional pressure wire-guided FFR/NHPR to direct PCI in patients with coronary artery disease.
This pivotal non-inferiority trial (≈1,924 patients) tests whether an FFRangio-guided strategy can match wire-based physiology for 1-year MACE while also evaluating procedure time, contrast and radiation dose, peri-procedural complications, patient-reported outcomes, usability, resource utilisation and cost-effectiveness. Optimised for contemporary cath lab practice, ALL-RISE addresses whether a wire-free, angiography-derived approach can become a new standard for physiology-guided PCI and which patients, lesions and centres are best suited to an FFRangio-first strategy.
Findings showed similar 1-year MACE outcomes in the FFRangio arm (6.9%) compared to the conventional wire-based arm (7.1%), meeting non-inferiority. FFRangio was faster to perform, and did not require additional procedural manipulation, unlike wire-based methods.
Interview Questions:
- What is the current role of coronary physiology in guiding PCI, and what are the limitations of the existing pressure wire-based approach?
- What were the aims of this trial?
- Can you walk us through the study design and patient population?
- What were the key findings?
- How do these results compare to previous data on angiography-derived versus invasive physiological assessment?
- What are the clinical implications for interventional cardiologists looking to adopt angiography-derived physiology in routine practice?
- What are the next steps for this research?
Recorded on-site at ACC.26, New Orleans.
For more expert insights and late-breaking science from ACC 2026, visit the Late-breaking Science Video Collection.
Editor: Jordan Rance
Videographer: Mike Knight
Support: This is an independent interview produced by Radcliffe Cardiology.
Keep up-to-date with our video collection from the American College of Cardiology's 75th Annual Scientific Session, bringing you the latest from late-breaking science, featured research, and clinical horizon sessions.
Catch our congress preview and wrap-up in the NVM Cardiology Meeting Reflections series, alongside concise Expert Interviews with leading faculty distilling the key take-home messages for clinical practice — plus in-depth Highlights breaking down the most impactful trials of the meeting.
More from this programme
Part 1
Late-Breaker Discussions
Part 2
Between the Sessions with Dr Purvi Parwani
Part 3
Expert Interviews
Part 4
Highlights
Part 5
Market Watch
Part 6
NVM Cardiology Meeting Reflections
Faculty Biographies
Ajay J Kirtane
Professor of Clinical Medicine
Ajay J Kirtane, is Professor of Medicine at the Columbia University Medical Center (CUMC) and Director of the Cardiac Catheterization Laboratories at NewYork-Presbyterian (NYP) Hospital / CUMC. Dr. Kirtane is an internationally-renowned leader in Interventional Cardiology, specializing in the care of patients with complex coronary and peripheral vascular disease.
In addition to his clinical commitments, Ajay has a strong interest in clinical education and research, serving as Chief Academic Officer of Columbia Interventional Cardiovascular Care. He is a director of the Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics conference, has served as a director of several international, national, and regional educational conferences, and has participated on the program committees for the scientific sessions of both the American College of Cardiology and American Heart Association. Ajay’s research…
Comments